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Graft failure is a severe treatment complication of unrelated donor umbilical cord blood transplantation
(UCBT). Its incidence seems to be higher after UCBT than after transplantation with bone marrow or
peripheral blood stem cells (PBSCs). The only curative option is to perform a second transplantation; however,
both the ideal stem cell source and the conditioning regimen for this salvage transplantation remain unclear.
We report a series of 11 patients who underwent haploidentical PBSC transplantation (PBSCT) as salvage
therapy for graft failure after a previous UCBT. The reduced-intensity conditioning regimen consisted of
ﬂudarabine 150 mg/m2 for 3 days and horse antithymocyte globulin 8 mg/kg for 4 days. Ex vivo CD34þ
positive selection was performed in all cases, and no post-transplantation graft-versus-host disease pro-
phylaxis was used. Six of the 9 evaluable patients (67%) eventually engrafted, at a median time of 10 days. The
cumulative incidence of engraftment at 28 days was 64% (95% conﬁdence interval [CI], 35% to 92%). Two
patients relapsed after PBSCT. The cumulative incidence of TRM was 55% at 2 years (95% CI, 25% to 84%), and
the probability of overall survival at 2 years was 36%. Our ﬁndings suggest that haploidentical ex vivo T cell
edepleted PBSCT is a feasible alternative for treating graft failure after UCBT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Graft failure is a life-threatening complication after allo-
geneic stem cell transplantation [1]. If autologous hemato-
poietic recovery does not occur, the only curative option for
these patients is to perform a second transplantation to
restore bone marrow (BM) function.
Single-unit unrelated donor cord blood transplantation
(UCBT) has been associated with a longer time to reach
engraftment and a higher incidence of graft failure compared
with transplantation with BM or peripheral blood stem cells
(PBSCs) [2,3]. Patients experiencing graft failure after UCBT
usually lack a suitable HLA-matched related or unrelated
adult healthy donor. For this reason, in this setting, the only
therapeutic option is to perform a second UCBT or a related
haploidentical BM transplantation or PBSC transplantation
(PBSCT).
A recent registry study analyzing different salvage stra-
tegies for graft failure after UCBT concluded that the use of
PBSCs seems to be related to better outcomes comparedwith
other stem cell sources [4]. The study population and
transplantation procedures in that study were highlyedgments on page 1063.
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14.03.024heterogeneous, however, no information was provided
regarding the use of ex vivo T celledepleted PBSC grafts.
The aim of the present single-institution study was to
analyze the feasibility and outcome of haploidentical PBSCT
with ex vivo T cell depletion by means of CD34þ selection as
salvage therapy for graft failure after UCBT.PATIENTS AND METHODS
Patients
Patients diagnosed with primary or secondary graft failure after UCBT
between 2003 and 2011 were eligible for enrollment if they met the
following criteria: availability of a suitable related haploidentical donor,
feasibility of a second transplantation according to the patient’s clinical
condition, and absence of refractory or relapsed disease after UCBT.
Primary graft failure after UCBT was deﬁned as the absence of
hematopoietic recovery without donor chimerism in patients surviving
more than 28 days after transplantation. Secondary graft failure was deﬁned
as the presence of severe pancytopenia with the absence of donor chime-
rism after previous successful engraftment.
The hospital’s Institutional Review Board approved the protocol. Writ-
ten informed consent was obtained from all patients according to the
Declaration of Helsinki.Timing and Donor Selection
Chimerism analysis was performed in BM samples on daysþ14 andþ28
after UCBT in all patients, as described previously [5]. In patients with mixed
donor chimerism on day þ14, another test was performed on day þ21. A
patient with no detectable donor chimerism on day þ28 was considered a
graft failure, and a donor search was immediately started within the family.
For patients without neutrophil recovery but with predominant donor
chimerism, follow-up with close monitoring was maintained, with weekly
chimerism analysis and daily blood counts.
An urgent donor search and evaluation was performed in the family.
When multiple suitable related haploidentical donors were available,
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F. Moscardó et al. / Biol Blood Marrow Transplant 20 (2014) 1056e1073 1061younger male donors were preferred. Donors with a KIR ligand mismatch in
the graft-versus-host direction were considered as well.
Conditioning Regimen and Graft-versus-Host Disease Prophylaxis
The treatment plans regarding UCBT, including graft selection, condi-
tioning regimen, immune suppression, and supportive care have been
reported in detail previously [6,7]. For haploidentical PBSCT, all patients
received a conditioning regimen consisting of ﬂudarabine 50 mg/m2/day for
3 days on days -5 to -3 and antithymocyte globulin (ATG; Thymoglobulin;
Genzyme Transplant, Cambridge, MA) 2 mg/kg for 4 days on days -5 to -2.
PBSC collection was performed after high-dose granulocyte colony-
stimulating factor (G-CSF) mobilization (20 mg/kg/day) targeting a prese-
lection CD34þ cell dose of 10  106/kg of recipient body weight. The grafts
were T cell depleted by means of CD34þ positive selection (Miltenyi Biotec,
Bergisch Gladbach, Germany). No graft-versus-host disease (GVHD) pro-
phylaxis was administered after transplantation.
Patients developing acute GVHD received methylprednisolone 2 mg/kg/
day as initial therapy, followed by ATG in refractory cases. Chronic GVHD
was treated with prednisone 1 mg/kg/day.
Supportive Care
Patients were nursed in high-efﬁciency particulate air-ﬁltered rooms.
Methylprednisolone 1 mg/kg, paracetamol 1 g, and dexchlorpheniramine
5 mg were administered 1 hour before and 4 hours after the start of
ATG infusion to prevent infusion reactions. G-CSF was administered s.c. at 5
mg/kg/day from day þ7 until neutrophil engraftment. All patients received
anti-infectious therapy with both broad-spectrum antibiotics and antifun-
gals. A mold-active azole (itraconazole or voriconazole) was administered
until day þ180 or the initiation of steroids to treat GVHD. Prophylaxis
against Pneumocystis jiroveci with cotrimoxazole was started after engraft-
ment on a twice-weekly schedule and maintained for a minimum of 1 year
or until immunosuppressive therapy was stopped. Pentamidine was used if
cotrimoxazole was contraindicated. All blood products were irradiated and
leukocyte-depleted. Cytomegalovirus-seropositive patients received high-
dose i.v. acyclovir 500 mg/m2/8 hours until neutrophil recovery. There-
after, valganciclovir 900 mg/day was given prophylactically as described
previously [8]. Nonspeciﬁc immunoglobulin was administered i.v. at a dose
of 500 mg/kg monthly during the ﬁrst year after transplantation. Serum
galactomannan aswell as cytomegalovirus and Epstein-Barr virus viral loads
were monitored once weekly for the ﬁrst 4 months, every 2 weeks for
the subsequent 2 months, and monthly thereafter up to 1 year after
transplantation.
Deﬁnitions and Statistics
Engraftmentwas deﬁned as an absolute neutrophil count of0.5109/L
on 3 consecutive days. Platelet recovery was deﬁned as a platelet count
of 20  109/L, without transfusion support, for 7 consecutive days. A
patient who survived more than 28 days after transplantation and failed to
achievemyeloid engraftment was considered a primary graft failure. Time to
myeloid engraftment or platelet recovery was deﬁned as the time to reach
the ﬁrst day of each designated term. Acute and chronic GVHDwere deﬁned
and graded according to standard criteria. Overall survival (OS) was deﬁned
as survival from the time of transplantation.
Statistical analyses of this series were performed using frequencies for
categorical variables and median values for continuous variables. The
probabilities of engraftment, nonrelapse mortality (NRM), and GVHD were
estimated by the cumulative incidence method (marginal probability) [9].
For cumulative incidence analyses of engraftment and GVHD, death in
complete remission was considered a competing cause of failure, whereas
relapse was the competing event for NRM. The probability of OS was
calculated by a unadjusted time-to-event analysis using Kaplan-Meier
estimates [10]. Follow-up of patients was updated on April 1, 2013. Statis-
tical analyses were performed with R version 2.12.2 (R Project for Statistical
Computing, Vienna, Austria).
RESULTS
Patients and Transplantation Characteristics
Between January 1997 and December 2012, 298 patients
underwent UCBT at our hospital. Of these patients, 18 expe-
rienced primary graft failure and 6 experienced secondary
graft failure. Thirteen of the 24 patients with graft failure
died during the neutropenic phase before a second trans-
plantation could be scheduled, leaving 11 patients (9 males
and 2 females; median age, 30 years; range, 17 to 55 years)
for the present analysis. Table 1 presents patient and trans-
plantation characteristics.
F. Moscardó et al. / Biol Blood Marrow Transplant 20 (2014) 1056e10731062In brief, 9 patients (82%) were diagnosed with a hema-
tologic malignancy. Seven patients (64%) experienced pri-
mary graft failure after UCBT, and the remaining 4 (36%)
experienced secondary graft failure with complete loss of
donor chimerism. The median interval from UCBT to salvage
transplantation was 46 days (range, 31 to 69 days), including
44 days (range, 36 to 64 days) in patients with primary graft
failure and 43 days (range, 31 to 69 days) in those with
secondary graft failure. No patient was discharged from
hospital before undergoing haploidentical PBSCT.
Themedian CD34þ cell dosewas 5.42106 per kg of body
weight receptor (range, 2.26 to 11.36  106), and the median
CD3þ cell dose was 4.9  103 per kg of body weight receptor
(range, 0.9 to 10.2  103).Engraftment
One patient died on day þ3 after haploidentical PBSCT,
and 1 patient experienced relapse at day þ14 without
achieving engraftment. Two patients (18%) were not evalu-
able for engraftment. Two of the patients evaluated for
engraftment experienced primary graft failure after hap-
loidentical PBSCT. The 2 nonengrafted patients died, on
day þ35 and day þ41. The remaining 7 patients successfully
engrafted, at a median of 10 days (range, 10 to 13 days). The
cumulative incidence of engraftment at 28 days was 64%
(95% conﬁdence interval [CI], 35% to 92%) (Figure 1). All
patients who engrafted successfully achieved platelet
recovery, at a median of 22 days (range, 15 to 55 days).GVHD, Relapse, and Survival
One patient presented with grade II acute GVHD on
day þ38 post-transplantation. This patient was treated with
prednisone at a dose of 2 mg/kg/day and achieved a clinical
response. Of the 6 evaluable patients, 2 were diagnosed with
extensive chronic GVHD, at day þ128 and day þ218. The
cumulative incidence of chronic GVHD was 33% at 2 years
(95% CI, 0% to 71%). Two patients (18%) experienced disease
relapse, 1 at day þ14 and the other at 3 years post-PBSCT.Figure 1. Cumulative incidence of engraftment in patients undergoing ex vivo
T celledepleted haploidentical PBSCT as salvage therapy for graft failure after
UCBT.Overall, 8 patients (73%) died, with a median follow-up of
107 days (range, 3 to 1390 days). Six patients died from
transplantation-related causes, including 3 from infection
after primary graft failure, 1 from Epstein-Barr viruserelated
non-Hodgkin lymphoma, 1 from cerebral bleeding, and
1 from infection not related to graft failure. The cumulative
incidence of NRM was 55% at 2 years (95% CI, 25% to 84%).
Three patients (27%) are still alive and disease free at
follow-up times of 993, 1526, and 1779 days after PBSCT. The
probability of OS was 36% at 2 years after salvage trans-
plantation (Figure 2).DISCUSSION
This study demonstrates that ex vivo T celledepleted
haploidentical PBSCT is a feasible alternative rescue salvage
therapy for primary and secondary graft failure after UCBT.
For the majority of evaluable patients, PBSCT resulted in
a rapid engraftment, with a median time to neutrophil
recovery of 10 days. All patients who engrafted also experi-
enced platelet recovery. The relatively young age of our study
population (median age, 30 years) should be taken into
account, and our ﬁndings might not apply to older patients.
To date, information regarding salvage therapy with PBSCT
for graft failure after UCBT is based on very small series and
case reports [4,11-14], none of which explored the role of
ex vivo T cell depletion in this setting.
The decision to rescue a graft failure and ﬁnally proceed
to salvage stem cell transplantation is often difﬁcult in the
UCBT setting. In fact, although the median time to neutrophil
recovery after UCBT in our center is 21 days, extremely
delayed engraftment exceeding 50 days is occasionally
observed. Thus, clinicians should be cautious and avoid
undertaking a second transplantation prematurely. The
absence of detectable donor chimerism or decreasing
kinetics of donor chimerism could aid the decision to initiate
salvage therapy.
Our treatment schedule was based on a reduced-
intensity, highly immunosuppressive conditioning regimen
to decrease the possibility of an immunologically mediatedFigure 2. OS in patients undergoing ex vivo T celledepleted haploidentical
PBSCT as salvage therapy for graft failure after UCBT.
F. Moscardó et al. / Biol Blood Marrow Transplant 20 (2014) 1056e1073 1063graft rejection. In fact, as reported previously by our group, all
patients with primary graft failure after UCBT presentedwith
mixed hematopoietic chimerism at day þ14, with a high
persistence of host hematopoiesis [5]. For this reason, both
the low number of stem cells infused and an immunologic
effect could be responsible for the graft failure. In addition, a
high degree of T cell depletion was obtained using a CD34þ
positive selection (approximately 103/kg of body weight
receptor CD3þ cells infused) for GVHD prevention [15].
This strategy resulted in very low rates of acute and
chronic GVHD without the use of post-transplantation
immunosuppression compared with other studies [14].
Two evaluable patients did not achieve engraftment, how-
ever, representing a 64% cumulative incidence of engraft-
ment at day þ28. This cumulative incidence is apparently
lower than that reported by Yoshihara et al. [14] using a
nonmyeloablative nonhomogeneous conditioning regimen
but without ex vivo T cell depletion.
Relapseoccurred in only 2patients, in 1patient aftera long
follow-up of 3 years. This low relapse rate is clearly inﬂuenced
by the high NRM rate. The cumulative incidence of NMR at 2
years was 55%. Six of 11 patients died early after trans-
plantation from treatment-related causes, including graft
failure. It should be kept in mind, however, that all of our
transplant recipients were very-high-risk patients, with a
median of 46 days of previous neutropenia. Moreover, all
were receiving anti-infectious therapy with both broad-
spectrum antibiotics and antifungals. Under these condi-
tions, theﬁnal 2-yearOSof 36% seems reasonable for a salvage
strategy. Japanese groups have published better results. Fuji
et al. [4] reported a 1-year OS of 58% in 24 patients, whereas
Yoshihara et al. [14] reported a 5-year disease-free survival of
56%. The sample size in those studies, as in ours, is too small to
allow us to draw any solid conclusions from these data. It is
possible that the use of Tcell depletion in our series adversely
affected the likelihood of engraftment and, consequently,
transplantation-related mortality. One way to reduce the
incidence of graft failure could be to infuse the highest
possible CD34þ cell dose; however, despite the use of high-
dose G-CSF, this would be difﬁcult in older donors, possibly
requiring more than 1 or 2 collection procedures.
In conclusion, ex vivo T celledepleted haploidentical
PBSCT is a feasible strategy with acceptable survival proba-
bility for patients experiencing graft failure after UCBT.AKNOWLEDGMENTS
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